Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-24T16:17:24.926Z Has data issue: false hasContentIssue false
  • English
  • Français

Topiramate related obsessive–compulsive disorder

Published online by Cambridge University Press:  16 April 2020

Cigdem Ozkara ,
Mine Ozmen ,
Ayten Erdogan  and
Irem Yalug
Cigdem Ozkara*
Affiliation:
Department of Neurology, Istanbul University, Cerrahpasa Medical Faculty, Cerrahpasa Cad, Kocamustafapasa, 34230, Istanbul, Turkey
Mine Ozmen
Affiliation:
Department of Psychiatry, Istanbul University, Cerrahpasa Medical Faculty, Cerrahpasa Cad, Kocamustafapasa, 34230, Istanbul, Turkey
Ayten Erdogan
Affiliation:
Department of Child and Adolescent Psychiatry, Istanbul University, Cerrahpasa Medical Faculty, Cerrahpasa Cad, Kocamostafapasa, 34230, Istanbul, Turkey
Irem Yalug
Affiliation:
Department of Psychiatry, Kocaeli University, Kocaeli Medical Faculty, Kocaeli, Turkey
*
*Corresponding author. E-mail address: cigdemoz@istanbul.edu.tr (C. Ozkara).
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

TopiramateEpilepsySide effectsObsessive–compulsive disorder
Type
Case report
Information
European Psychiatry , Volume 20 , Issue 1 , January 2005 , pp. 78 - 79
Copyright
Copyright © Elsevier SAS 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Abbreviations: TPM, Topiramate; AED, anti-epileptic drug; OCD, obsessive-compulsive disorder; CBZ, carbamazepine; LTG, lamotrigine; MRI, magnetic resonance imaging; EEG, electroencephalography; YBOCS, Yale Brown Obsessive Compulsive Scale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders.

References

Dannon, PNTopiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol 2003;26(1):1–4.CrossRefGoogle ScholarPubMed
Hirai, K, Kimiya, S, Tabata, K, Seki, T, Jozaki, KSelective mutism and obsessive compulsive disorders associated with zonisamide. Seizur 2002;11:468–470.CrossRefGoogle ScholarPubMed
Kanner, AM, Wuu, J, Faught, E, Tatum, WO, Fix, A, French, JAA past psychiatric history may be a risk factor for topiramate -related psychiatric and cognitive adverse events. Epilepsy Behav 2003;4(5):548–552.CrossRefGoogle ScholarPubMed
Marsh, L, Rao, VPsychiatric complications in patients with epilepsy: a review. Epilepsy Res 2002;49:11–13.CrossRefGoogle ScholarPubMed
Mathew, NT, Kailasam, J, Meadors, LProphylaxis of migraine, transformed migraine and cluster headache with topiramate. Headach 2002;42:796–803.CrossRefGoogle ScholarPubMed
Mula, M, Trimble, MRThe importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav 2003;4(3):430–434.CrossRefGoogle ScholarPubMed
Pauls, LDThe role of genetic factors in OCD. In: Fineberg, PN, Marazziti, D, Stein, D eds. Obsessive compulsive disorder: a practical guid London: Taylor & Francis; 2001. 61–77.Google Scholar
Perucca, EA pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997;35:241–256.CrossRefGoogle ScholarPubMed
Roy, KN, Chengappa, J, Levine, D, Rathore, H, Parepally, , Atzert, RLong-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatr 2001;16:186–190.Google Scholar
Submit a response

Comments

No Comments have been published for this article.